Arrowhead Research

Shares of Arrowhead Research Corp (NASDAQ: ARWR) lost more than 50 percent from a year ago. Edward Tenthoff of Piper Jaffray left Arrowhead's R&D day "more confident" that the company's ARC-520 is an active drug for HBV. Tenthoff maintained an Overweight rating with a price target boosted to $...